التفاصيل البيبلوغرافية
| العنوان: |
Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study. |
| المؤلفون: |
Minato, Akinori, Furubayashi, Nobuki, Nagata, Yujiro, Tomoda, Toshihisa, Masaoka, Hiroyuki, Song, Yoohyun, Hori, Yoshifumi, Kiyoshima, Keijiro, Negishi, Takahito, Kuroiwa, Kentaro, Seki, Narihito, Tomisaki, Ikko, Harada, Kenichi, Nakamura, Motonobu, Fujimoto, Naohiro |
| المصدر: |
Current Oncology; Feb2024, Vol. 31 Issue 2, p862-871, 10p |
| مصطلحات موضوعية: |
TRANSITIONAL cell carcinoma, CANCER patients, METASTASIS, IMMUNE checkpoint proteins, URINARY organs |
| مستخلص: |
Subtype of urothelial carcinoma (SUC), defined here as urothelial carcinoma with any histologic subtype or divergent differentiation, is a clinically aggressive disease. However, the efficacy of enfortumab vedotin (EV) against SUC remains unclear. Hence, this study aimed to assess the oncological outcomes of patients with SUC treated with EV for metastatic disease. We retrospectively evaluated consecutive patients with advanced lower and upper urinary tract cancer who received EV after platinum-based chemotherapy and immune checkpoint blockade therapy at six institutions. The objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were compared between patients with pure urothelial carcinoma (PUC) and those with SUC. We identified 44 and 18 patients with PUC and SUC, respectively. Squamous differentiation was the most common subtype element, followed by glandular differentiation and sarcomatoid subtype. Although patients with SUC had a comparable ORR to those with PUC, the duration of response for SUC was short. Patients with SUC had poorer PFS than those with PUC; however, no significant difference was observed in OS. Multivariate analysis revealed that SUC was significantly associated with shorter PFS. Although the response of metastatic SUC to EV was similar to that of PUC, SUC showed faster progression than PUC. [ABSTRACT FROM AUTHOR] |
|
Copyright of Current Oncology is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder